The Alpha-1 Antitrypsin Deficiency (A1AD) drugs in development market research report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Alpha-1 Antitrypsin Deficiency (A1AD). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Alpha-1 Antitrypsin Deficiency (A1AD) by 38 companies/universities/institutes. The top development phase for Alpha-1 Antitrypsin Deficiency (A1AD) is preclinical with 22 drugs in that stage. The Alpha-1 Antitrypsin Deficiency (A1AD) pipeline has 44 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline products market are: Vertex Pharmaceuticals, Intellia Therapeutics and Novo Nordisk.

The key targets in the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline products market include Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1), Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37), and Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1).

The key mechanisms of action in the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline product include Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1) Activator with 19 drugs in Phase I. The Alpha-1 Antitrypsin Deficiency (A1AD) pipeline products include five routes of administration with the top ROA being Oral and eight key molecule types in the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline products market including Gene Therapy, and Small Molecule.

Alpha-1 Antitrypsin Deficiency (A1AD) overview

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes, and infections.

For a complete picture of Alpha-1 Antitrypsin Deficiency (A1AD)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.